Update 05 Jan 2021:

The purpose of this update is to provide Q&A #4 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #4 file.

********************************************************************************************************

Update 31 Dec 2020:

The purpose of this update is to provide Q&A #3 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #3 file.

***********************************************************************************************************

Update 29 Dec 2020:

The purpose of this update is to provide Q&A #2 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #2 file.

***********************************************************************************************************

Update 22 Dec 2020:

The purpose of this update is to provide Q&A #1 for the RFI: COVID Screening Testing of Asymptomatic Individuals.  This will provide clarifications to questions asked since the RFI has been posted.

The due date for the "COVID-19 Screening" responses remains unchanged at 06 January 2021. The Government does not intend to extend the due date for the responses based on the clarifications annotated in the attached Q&A #1 file.

************************************************************************************************************

Description

Pursuant to Federal Acquisition Regulation (FAR) 15.201(e), this notice is issued as a Request for Information (RFI).  The Naval Air Systems Command is conducting market research to explore industry solutions related to FDA/EUA approved COVID 19 Testing options available in the commercial marketplace.  NAVAIR’s goal is to rapidly identify asymptomatic COVID-19 positive personnel in our on-station workforce as quickly as possible following an administered test.

Background

In response to the COVID pandemic, NAVAIR is seeking industry partners with a capability and capacity to immediately conduct regular, recurring and targeted COVID screening testing.  The below links within Supporting Information helped to inform NAVAIR’s requirement.  Please ensure your responses consider the information outlined in the CDC and NIH documents linked below.

Relevant Information

• Mass screening - This requirement may be fulfilled by either PCR molecular testing or antigen testing.  However, NAVAIR has a preference for PCR molecular testing with results reported within 24-48 hours.  Please describe your company’s ability to meet this requirement.  If your company does not provide PCR level testing, please explain an antigen based or other solution and address any specialized medical support that may be needed to administer such test.
• Targeted Screening – NAVAIR has a need to test small, high risk populations on an ad-hoc and/or daily basis.  These results are desired within one hour or less.  Please include in your response your capability to meet this requirement, how the test will be administered, how the individual results will be provided and address any specialized medical support that may be needed to administer such test 
• Reference Supporting Information #5, please include a response to your ability to meet the minimum, average and maximum proposed quantities by NAVAIR location.
• For mass screening and targeted screening, please ensure your response includes the COVID test name; FDA status (EUA, Off-Label usage, etc.); Lab CLIA Certificate Number; number of geographic sites that can be supported; number of tests per week/day that can be supported; how the test will be administered; turn-around time in hours for results; identification of any resources to be provided by the Government to assist in test administration; any new technologies you are pursuing to include status of FDA/EUA approval; and describe method for reporting to all applicable organizations (i.e. state health departments, individuals, NAVAIR, etc.)   
• Please describe any constraints regarding capacity, other customer needs, etc.
• Please provide a list of existing Federal and State Government contracts
• Please provide Rough Order of Magnitude (ROM) pricing for the requirements outlined herein

Supporting Information

The following links were used to inform this Sources Sought

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325181/ - The importance of test sensitivity versus frequency and turnaround time.
2. https://www.cdc.gov/coronavirus/2019-ncov/php/open-america/expanded-screening-testing.html - CDC report on use of asymptomatic COVID screening to reduce transmission
3. https://www.cdc.gov/mmwr/volumes/69/wr/mm6949e2.htm - CDC guidance on the importance of increased testing to identify asymptomatic individuals
4. ACRONYMS
   1. EUA – Emergency Use Authorization
   2. CLIA – Clinical Laboratory Improvement Amendments
   3. FDA- Food and Drug Administration
5. NAVAIR site location requirements:

Naval Base

Location

Geographic Zone

Targeted Weekly Screening Requirement

Minimum Weekly  Screening Requirement (10% of onsite population)

Average Weekly  Screening   Requirement (50% of onsite population)

Maximum Weekly Screening Requirements

Joint Base Lakehurst

Lakehurst, NJ

1

100

40

200

400

NAS Patuxent River

Patuxent River, MD

1

600

616

3,087

6,174

Webster Outlying Field

St. Inigoes, MD

1

75

70

350

700

NAS Oceana

Virginia Beach, VA

2

48

261

1,306

2,612

MCAS Cherry Point

Cherry Point, NC

2

344

344

1,721

3,442

NAS Jacksonville

Jacksonville, FL

2

274

473

2,365

4,730

NSA Orlando

Orlando, FL

2

43

40

200

400

NAS Whidbey Island

Whidbey Island, WA

3

15

97

483

966

NAS Lemoore

Lemoore, CA

3

18

123

613

1,226

NAWS China Lake

China Lake, CA

3

140

469

2,345

4,690

NAS Point Mugu

Point Mugu, CA

3

200

192

959

1,918

NAS North Island

San Diego, CA

3

304

473

2,366

4,732

TOTALS

 2,161

3,198

15,990

31,990

Due Date

• Please respond no later than 06 January 2021.  All questions must be sent to [email protected] and [email protected] with "COVID-19 Screening" in the subject line.

DISCLAIMER: 

• This announcement is for informational purposes only and does not commit the Government to award a contract as a result of this announcement.  This does not constitute a RFP or a promise to issue a RFP in the future. Further, the Government is not seeking proposals at this time and will not accept unsolicited proposals.
• The information provided herein is for informational purposes only. These requirements are subject to change based on the Government’s need. The final requirement, if any, will be defined under a formal RFP/RFQ. Not responding to this announcement does not preclude participation in any future RFP/RFQ, if issued. If a RFP/RFQ is released, it will be posted on the https://beta.sam.gov website. Any subsequent amendments will also be posted to the https://beta.sam.gov website. It is the responsibility of the potential offerors to monitor this website for additional information pertaining to this requirement.
• Respondents are advised that the Government will not pay for any information or administrative costs incurred in response to this announcement. All costs associated with responding to this announcement will be solely at the expense of the interested party.